Monoaminergic Drive and Discoordination Following Stroke
中风后的单胺能驱动和协调障碍
基本信息
- 批准号:7435312
- 负责人:
- 金额:$ 27.81万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2005
- 资助国家:美国
- 起止时间:2005-09-15 至 2010-05-31
- 项目状态:已结题
- 来源:
- 关键词:AffectAgonistAutomobile DrivingAutoreceptorsBrain StemChronicConditionCouplingDepressed moodDevelopmentDyskinetic syndromeElbowFoundationsFreedomGenerationsH-ReflexHyperactive behaviorIndividualIntentionInterneuronsInterventionIsometric ExerciseJointsKnowledgeLimb structureMeasuresMediatingMotorMotor NeuronsMovementMuscleNeuronsOutcomePathway interactionsPatternPharmaceutical PreparationsReflex actionRelianceRoleRotationShockShoulderSourceSpinalSpinal CordStrokeSystemTorqueUpper ExtremityUpper armWithdrawalalpha 2 agonisthemiparetic strokemonoaminenoradrenergicnovelreceptorrelating to nervous systemspinal reflexstretch reflextamsulosintizanidinetransmission processvibration
项目摘要
DESCRIPTION (provided by applicant): Movement discoordination following stroke is caused by the emergence of stereotypic multi-joint movement patterns, reflecting a loss of independent joint control, and hyperactivity of spinal reflexes including the stretch reflex (spasticity) and the flexion withdrawal reflex. The commonality between the emergence of abnormal synergies and spinal reflex hyperexcitability following stroke is postulated to arise from an increased bulbospinal monoaminergic drive to the spinal cord following a loss of corticospinal and corticobulbar projections. Evidence for increased bulbospinal input include increased motoneuron excitability, depressed short latency and enhanced long latency flexion reflexes, and a diminished capacity for selective movement due to the emergence of stereotypic synergic movement patterns. We propose to examine the effect of an increased bulbospinal monoaminergic drive on the expression of abnormal movement patterns and spinal reflexes following stroke by manipulating the neural excitability at the spinal cord and/or brainstem using either Tizanidine (TIZ) or Tamsulosin (TAM). It is our intention to: 1) identify and quantify the presence of increased noradrenergic input to the spinal cord following a stroke; 2) elucidate mechanisms underlying hyperactive flexion and stretch reflexes following stroke; 3) investigate the role of monoaminergic pathways in the expression of abnormal muscle and torque synergies under isometric and dynamic conditions in the paretic upper limb following stroke. We predict that inhibition of brainstem monoaminergic pathways as well as group II and high threshold afferents at the cord, through administration of a noradrenergic (NE) a-2 agonist (TIZ), will result in the reduction of discoordination, flexion reflexes and spasticity in individuals with stroke. We also predict that reduction of NE mediated excitation of motoneurons, through the administration of a selective NE a-1 antagonist (TAM), will result in the reduction of volitional strength, spasticity, and magnitude of the flexion reflex. Upper extremity discoordination is expected to remain unaltered by the administration of TAM because of its lack of supraspinal effects. The knowledge generated by this study seeks to reveal the primary mechanisms underlying the presence of discoordination and hyperactive spinal reflexes following stroke. The identification of these mechanisms may direct the development of novel pharmacological agents that target bulbospinal mechanisms underpinning upper extremity discoordination
描述(由申请人提供):卒中后的运动失调是由刻板的多关节运动模式的出现引起的,反映了独立关节控制的丧失和脊髓反射的过度活跃,包括牵张反射(痉挛状态)和屈曲撤回反射。脑卒中后出现异常协同作用和脊髓反射性兴奋过度之间的共性被认为是由于皮质脊髓和皮质延髓投射丧失后球脊髓单胺能驱动脊髓增加所致。球脊髓输入增加的证据包括运动神经元兴奋性增加、短潜伏期降低和长潜伏期屈曲反射增强,以及由于刻板协同运动模式的出现而导致的选择性运动能力降低。我们建议检查的影响,增加球脊髓单胺能驱动器的表达异常运动模式和脊髓反射中风后操纵神经兴奋性在脊髓和/或脑干使用替扎尼定(TIZ)或坦索罗辛(TAM)。我们打算:1)识别和量化卒中后脊髓去甲肾上腺素能输入增加的存在; 2)阐明卒中后过度活跃的屈曲和伸展反射的潜在机制; 3)研究卒中后麻痹上肢在等长和动态条件下单胺能通路在异常肌肉和扭矩协同作用表达中的作用。我们预测,抑制脑干单胺能通路,以及第二组和高阈值传入在脊髓,通过管理的去甲肾上腺素(NE)的α-2激动剂(TIZ),将导致减少失调,屈曲反射和痉挛的个人中风。我们还预测,减少NE介导的运动神经元的兴奋,通过管理的选择性NE a-1拮抗剂(TAM),将导致意志强度,痉挛,屈曲反射的幅度减少。由于缺乏脊髓上的作用,预计TAM给药后上肢不协调不会改变。本研究所产生的知识旨在揭示中风后存在不协调和脊髓反射亢进的主要机制。这些机制的确定可能会指导开发新的药理学药物,靶向支撑上肢不协调的球脊髓机制
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JULIUS P DEWALD其他文献
JULIUS P DEWALD的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JULIUS P DEWALD', 18)}}的其他基金
Contralesional Corticobulbospinal Structural and Functional Changes Post Stroke: Biomarkers for the upper limb flexion synergy
中风后对侧皮质球脊髓结构和功能变化:上肢屈曲协同作用的生物标志物
- 批准号:
10741103 - 财政年份:2023
- 资助金额:
$ 27.81万 - 项目类别:
Determination of the Recruitment of Indirect Motor Pathways in Chronic Hemiparetic Stroke
慢性偏瘫中风间接运动通路募集的测定
- 批准号:
9978864 - 财政年份:2019
- 资助金额:
$ 27.81万 - 项目类别:
Contralesional Corticobulbospinal Structural and Functional Changes Post Stroke: Biomarkers for the upper limb flexion synergy
中风后对侧皮质球脊髓结构和功能变化:上肢屈曲协同作用的生物标志物
- 批准号:
10832173 - 财政年份:2019
- 资助金额:
$ 27.81万 - 项目类别:
Determination of the Recruitment of Indirect Motor Pathways in Chronic Hemiparetic Stroke
慢性偏瘫中风间接运动通路募集的测定
- 批准号:
9809617 - 财政年份:2019
- 资助金额:
$ 27.81万 - 项目类别:
Contralesional Corticobulbospinal Structural and Functional Changes Post Stroke: Biomarkers for the upper limb flexion synergy
中风后对侧皮质球脊髓结构和功能变化:上肢屈曲协同作用的生物标志物
- 批准号:
10378022 - 财政年份:2019
- 资助金额:
$ 27.81万 - 项目类别:
Contralesional Corticobulbospinal Structural and Functional Changes Post Stroke: Biomarkers for the upper limb flexion synergy
中风后对侧皮质球脊髓结构和功能变化:上肢屈曲协同作用的生物标志物
- 批准号:
10624767 - 财政年份:2019
- 资助金额:
$ 27.81万 - 项目类别:
Contralesional Corticobulbospinal Structural and Functional Changes Post Stroke: Biomarkers for the upper limb flexion synergy
中风后对侧皮质球脊髓结构和功能变化:上肢屈曲协同作用的生物标志物
- 批准号:
9914139 - 财政年份:2019
- 资助金额:
$ 27.81万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 27.81万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 27.81万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 27.81万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 27.81万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 27.81万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 27.81万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 27.81万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 27.81万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 27.81万 - 项目类别:
Identification and characterization of a plant growth promoter from wild plants: is this a novel plant hormone agonist?
野生植物中植物生长促进剂的鉴定和表征:这是一种新型植物激素激动剂吗?
- 批准号:
23K05057 - 财政年份:2023
- 资助金额:
$ 27.81万 - 项目类别:
Grant-in-Aid for Scientific Research (C)